Skip to main content

Table 3 Deterministic cost - effectiveness results of Base Case Lifetime Analysis

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

 

Ivabradine + Standard therapy

Standard therapy

Incremental

Costs

   

Total costs (€)

8,655

5,873

2,792

Drug acquisition cost (€)

5,340

2,374

2,966

Hospitalization costs (€)

1,833

1,781

52

HF management costs (€)

1,492

1,754

−262

Health outcomes

   

QALYs

4.27

3.99

0.28

LYs

5.86

5.61

0.25

Incremental analysis

   

ICER per QALY (€)

  

9,986

ICER per LY (€)

  

11,002

  1. ICER: incremental-cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted-life-year.